Jianying Xiao has over 16 years of experience in pharmaceutical research. She has expertise in in vivo and in vitro drug discovery techniques related to drug metabolism, infectious diseases, immunology, and cardio-metabolic disorders. She is proficient in various research techniques including animal handling, molecular biology, cell culture, and data analysis software. Jianying has worked at Merck & Co. for over 18 years, leading numerous projects that resulted in publications, patents, and awards. Her work has advanced drug programs from research through clinical trials.

1. JIANYING XIAO
xjy6610@gmail.com https://www.linkedin.com/in/xiao-jianying-02b4a636 (732)822-9994
HIGHLY SKILLED SCIENTIST
Medical training and 16+ years of intensive research experience in world's top pharmaceutical companies working in
both in vivo and in vitro aspects of drug discovery in drug metabolism, infectious diseases, immunology and cardio-
metabolic disorders areas. Recognized critical thinker with excellent organizational skills; flexible and versatile
scientist with an exceptional ability of quick learning; and a recipient of multiple Awards of Excellence for
contributions to pipelines.
RESEARCH TECHNICAL & CLINICAL EXPERTISE
In-Vivo Skills
Proficient in small and large (rabbits, dogs) laboratory animal handling, including expertise in retro-orbital bleeding,
rodent surgery and dog urethral catheterization, mouse bronchoalveolar Lavage fluid collection
Immunology
Basic and advanced immunology techniques, including, FACS, T cell proliferation, active and passive immunization
study, antibody preparation, IHC, TDAR and TIDAR models.
Molecular Biology and Biochemistry
Proficient in nucleic acid and protein techniques including: RT-PCR, quantitative PCR, protein expression, enzymatic
assays and in vitro transcription/translation., and HPLC.
Cell Biolog
Proficient in cell culture, cell lines, primary cells and bacterial culture.
Computer
Proficient in Telemetry BP Analysis, GraphPad Prism, Gene bank, Word, Excel and PowerPoint.
Clinical Skills
In charge of 15 ~19 beds in Hospital. Managed patients’ medical data and treatment, performed procedures and
clinical trials
WORK EXPERIENCE
MERCK & Co., Inc. Kenilworth, NJ 2000 – Present
PHARMACOLOGY Dept. 2009 – Present
Infectious disease:
o Established lung epithelial ling fluid (ELF) PK
Characterized one PCC and potential backups by analyzing bronchoalveolar lavage fluid (BALF) and
serum pharmacokinetics correlation in the lung infection model using clinically relevant bacterial
strains
o Finished post marketing support to one mediceine: work resulted in an abstract, a paper is in
preparation and an Award of Excellence.
Multiple MRSA and MSSA strains were used in mouse thigh infection model under immune
competent and immune suppression condition to test the medicine and the standard of care Linezolid.
Studies demonstrated antibiotics efficacious in mice with neutropenia. The results suggested that the warning
label for the medicine should be removed.
o Wall Teichoic Acid Program: work resulted in two published papers and one abstract.
Identified key elements for in-vivo Frequency of Resistance (FOR) study to advance the program
Characterized Staphylococcal Wall Teichoic Acid 2-Epimerases WT and mutant strains.
Immunology: Work resulted in an abstract and won an Award of Excellence.
o Established the T-cell dependent and independent antibody response models (TDAR & TIDAR) in support
of programs. After models were validated in house, collaboartivelly outsourced the models to an external
provider.
Cardiovascular disease: Work resulted in one abstract abstract and an Award of Excellence.
o Developed Dahl Salt Sensitive(DSS) model of chronic kidney disease, validated with Enalapril. This model
provides a valuable tool to evaluate the kidney protective potential of antihypertencsinve agents.
1

2. o Developed an adriamycin-induced kideny disease model in support of one Project.
Diabetes: Support GPR119, GPR40 Agonist & AMPK Activator Programs. This work resulted in two
Awards of Excellence. 1 PCC was approved
o Designed and conducted the 2 critical mouse studies which led to a GO decision.
o Established & validated HGI study by execution ABS (Automated Blood Sampler) platform with SoCs.
Leads were tested comb with DPPIV inhibitor in chronic rat study, the data showed there is synergic effect
of GLP-1over 24hrs which is decision–driven.
o Designed, conducted and expedited PK/PD assay to key compounds using the ABS platform to guide early
clinical development of MK8655. Demonstrated that the effects of GPR40 Agonists did increase Insulin &
C-peptide secretion, but the use of the ABS approach did not enhance sensitivity for PK/PD assessments.
o Validated the use 3-mercaptopicolinic acid (3-MPA) (PEPCK inhibitor), D2O and U-13C glucose as tracers
to evaluate the effects of GPR40 Agonists on glucose pathway in Wistar and GK rats.
o Coordinated the Portal Vein Pulsatility studies in GK or Wistar rats, demonstrated that GPR40 agonist
increase insulin pulsatility. and optimized blood collection method to advance biomarker studies.
Obesity: Contribued to DGAT1 /MGAT2/ PrCP Inhibitor programs by performing key assays which led to
GO/NO-GO decisions . This work resulted in 5 published papers, 7 abstracts and two Awards of
Excellence.
o Key player who performed chronic and sub-chronic studies to evaluate MOA and biomarkers, and supported
SAR.
ATHEROSCLEROSIS & HYPERTENSION Dept. 2001 – 2009
11β HSD-1 program: Key contributor to the identification of potent and selective inhibitors of 11β-HSD1 for
the treatment of metabolic syndrome. As a result of this work, 5 PCCs were approved, 5 papers, 8 abstracts
and one patent were published, and 3 Awards of Excellence were granted.
o Developed an effective and direct method to measure ex- vivo cortisone conversion in tissues. This method
was used to evaluate key compounds in tissues of different species and to characterize the kinetics of
compounds in cobination with the SHR BP efficacy model, and the driver for the development of 11b-HSD-
1 inhibitors. This innovation was granted a U.S.A patent.
o The immunological effect of HSD-1 inhibition was evaluated using the OVA-induced lung allergic mouse
model.
ROMK Inhibitor program: 1 PCC was approved and 2 papers were published.
o Supported the program with key assays such as acute diuresis in rats & dogs, BP study in telemetry rats and
aldosterone assay
NO-ARB & NO- CICLETANINE program:
o Performed in vivo studies to identify slow-release formulation of L-736 & Developed a rodent model to
address the metabolic liabilities of HCTZ.
SGK1 & SGC program: one abstract was published
o Optimized and validated Nuclear translocation assay (GFP - Forkhead (FKHRL1) translocation assay) which
was used to identify potent inhibitors of SGK1 to treat hypertension.
IMMUNOLOGY Dept. 2000 – 2001
VLA-4 program: One paper and one abstract were published
o Refined the inflammation model of ova transgenic mice, by establishing a transfer model using cultured
primary Th0, Th1, Th2 and Th1, Th2 together. Gained a better understanding of the OVA induced
inflammation, and demonstrated that compounds that affect T cell activation and cell trafficking are most
efficacious. Investigated the mechanism of lymphocytosis caused by VLA-4 antagonists and homing of
lymphoid cells.
PRIOR WORKING EXPERIENCE
DuPont PHARMACEUTICALS COMPANY Newark, DE
Drug metabolism: Expression and Determination of P450 and Human NADPH-P450 Oxidoreductase in
Baculovirus - insect cell system (Sf9) were efficiently performed and program was advanced ahead of time.
STATE UNIVERSITY of NEW YORK Buffalo, NY
2

3. Dept. of Pharmaceutics & Biological Sciences
o Investigated the mechanism of inhibition MRP by flavonoids & Characterized sodium-dependent sulfate
cotransporter (NaSi-1) in HK-2 cell line.
o Designed and derivated antisense RNA of Slowpoke in Drosophila, cloned genes related to heart-beat rate of
Drosophila.
BEIJING YOUAN HOSPITAL, CAPITAL MEDICAl UNIVERSITY Beijing, China
o Established immune response induced hepatic fibrosis in Wistar rats, the anti-fibrosis effect of Shuganmei
was tested.
o Prepared alkaline phosphatase conjugated Laminin antibody to test clinical samples to monitor liver fibrosis
progress.
o In- charge of 15-19 beds in hospital and investigated Delta hepatitis in hepatitis B patients and performed
Efficacy of LAK cell on chronic hepatitis clinical trial.
EDUCATION
• M.S. of Biological Science, State University of New York, Buffalo, NY,
• M.S. of Medicine, Department of Medicine, Capital University of Medical Sciences
• Bachelor of Medicine, Department of Medicine, Chongqing Medical University
Publications
1. Caryn Hampton, Xiaoyan Zhou, Birgit T. Priest, Lee-Yuh Pai, John P. Felix, Brande Thomas-Fowlkes, Jessica Liu,
Martin Kohler, Jianying Xiao, Aaron Corona, Olga Price, Charles Gill, Kashmira Shah, Cordelia Rasa,Vince Tong,
Karen Owens, James Ormes, Haifeng Tang, Sophie Roy, Kathleen A. Sullivan, Joseph M. Metzger, Magdalena Alonso-
Galicia,Gregory J. Kaczorowski, Alexander Pasternak, and Maria L. Garcia. The renal outer medullary potassium
channel inhibitor, MK-71445, lowers blood pressure and manifests features of Bartter's syndrome type II phenotype is
accepted for publication in the Journal of Pharmacology and Experimental Therapeutics (JPET). 14th
Jul. 2016
2. Paul A. Mann, Anna Müller, Kerstin A. Wolff, Thierry Fischmann, Hao Wang, Patricia Reed, Yan Hou, Wenjin Li,
Christa E. Müller5, Jianying Xiao, Nicholas Murgolo, Xinwei Sher, Todd Mayhood, Payal R. Sheth, Asra Mirza, Marc
Labroli, Li Xiao, Mark McCoy, Charles J. Gill, Mariana G. Pinho,Tanja Schneider, Terry Roemer Chemical Genetic
Analysis and Functional Characterization of Staphylococcal Wall Teichoic Acid 2-Epimerases Reveals Unconventional
Antibiotic Drug Targets. PLoS Pathog. 2016 May 4; 12 (5):e1005585
3. Lee, S.H, H. Wang, M. Labroli, S. Koseoglu, P. Zuck, T. Mayhood, C. Gill, P. Mann, X. Sher, S. Ha, S.-W. Yang, M.
Mandal, C. Yang, L. Liang, Z. Tan, P. Tawa, Y. Hou, R. Kuvelkar, K. DeVito, X. Wen, J. Xiao, M. Batchlett, C.J.
Balibar, J. Liu, J. Xiao, N. Murgolo, C.G. Garlisi, P.R. Sheth, A. Flattery, J. Su, C. Tan and T. Roemer. 2016. TarO-
specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci.
Sci Transl Med. 8:329ra32.
4. Shuwen He, Qingmei Hong, Zhong Lai, David X. Yang, Pauline C. Ting, Jeffrey T. Kuethe, Timothy A. Cernak,
Kevin D. Dykstra, Donald M. Sperbeck, Zhicai Wu, Yang Yu, Ginger X. Yang, Tianying Jian, Jian Liu, Deodial
Guiadeen, Arto D. Krikorian, Lisa M. Sonatore, Judyann Wiltsie, Jinqi Liu, Judith N. Gorski, Christine C. Chung, Jack
T. Gibson, JeanMarie Lisnock, Jianying Xiao, Michael Wolff, Sharon X. Tong, Maria Madeira, Bindhu V. Karanam,
Dong-Ming Shen, James M. Balkovec, Shirly Pinto, Ravi P. Nargund, and Robert J. DeVita. Discovery of a
Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety ACS Med.
Chem. Lett., Sep. 2014, 5 (10), pp 1082–1087
5. Maria L. Garcia, Birgit T. Priest, Magdalena Alonso-Galicia, Xiaoyan Zhou, John P. Felix, Richard M. Brochu, Timothy
Bailey, Andrew Swensen, Lee-Yuh Pai, Jianying Xiao, Melba Hernandez, Kimberly Hoagland, Karen Owens, Haifeng
Tang, Sophie Roy, Gregory J. Kaczorowski, and Alexander Pasternak. Pharmacological inhibition of the renal outer
medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis J Pharmacol Exp Ther. 2014
Jan; 348(1):153-64.
6. Liu J, Gorski JN, Gold SJ, Chen D, Chen S, Forrest G, Itoh Y, Marsh DJ, McLaren DG, Shen Z, Sonatore L,
Carballo-Jane E, Craw S, Guan X, Karanam B, Sakaki J, Szeto D, Tong X, Xiao J, Yoshimoto R, Yu H, Roddy TP,
Balkovec J, Pinto S. Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates
gut peptide release--potential insight into mechanism of action. Obesity (Silver Spring). 2013 Jul; 21(7):1406-15. doi:
10.1002/oby.20193. Epub 2013 May 13.
3

4. 7. Lin HV1, Chen D, Shen Z, Zhu L, Ouyang X, Vongs A, Kan Y, Levorse JM, Kowalik EJ Jr, Szeto DM, Yao X, Xiao J,
Chen S, Liu J, Garcia-Calvo M, Shin MK, Pinto S. Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs
postprandial gut hormone release. PLoS One. 2013; 8(1): e54480
8. Grah am TH1, Liu W, Verras A, Reibarkh M, Bleasby K, Bhatt UR, Chen Q, Garcia-Calvo M, Geissler WM, Gorski
JN, He H, Lassman ME, Lisnock J, Li X, Shen Z, Tong X, Tung EC, Wiltsie J, Xie D, Xu S, Xiao J, Hale JJ, Pinto S,
Shen DM. A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes. Bioorg Med Chem
Lett. 2012 Apr 15;22(8):2818-22.
9. Graham TH, Liu W, Verras A, Sebhat IK, Xiong Y, Bleasby K, Bhatt UR, Chen Q, Garcia-Calvo M, Geissler WM,
Gorski JN, He H, Lassman ME, Lisnock J, Li X, Shen Z, Tong X, Tung EC, Wiltsie J, Xiao J, Xie D, Xu S, Hale JJ,
Pinto S, Shen DM. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation. Bioorg
Med Chem Lett. 2012 Apr 15; 22(8):2811-7
10. Liu, J., GorskI, J.N., Gold, S.J., Chen, D., Chen, S., Forrest, G., He, T.Y., Itoh, Y., Marsh, D.J., Mclaren, D.G., Shen,
Z., Sonatore, L.M., Lisnock, J., Carballo-Jane, E., Craw, S., Guan, X., Karanam, B.V., Sakaki, J., Szeto, D.M., Tong,
X.S., Xiao, J., Yoshimoto, R., Yu, H., Balkovec, J.M. and Pinto, S.* Mechanism of action study of a novel, selective
small molecule diacylglycerol acyltransferase-1 inhibitor. For submission to: Endocrinology
11. Xia Yang,, Larry Peterson, Rolf Thieringer, Joshua L. Deignan, Xuping Wang, Jun Zhu,, Susanna Wang, Hua Zhong,,
Serguei Stepaniants, John Beaulaurier, I-Ming Wang, Ray Rosa, Anne-Marie Cumiskey, Jane Ming-Juan Luo, Qi Luo,
Kashmira Shah, Jianying Xiao, David Nickle, Andrew Plump, Eric E. Schadt, Aldons J. Lusis, and Pek Yee Lum,
Identification and validation of genes affecting aortic lesions in mice. Clin Invest. 2010 July 1; 120(7): 2414–2422.
12. Feng, Y., Guan, X., Li, J., Wu, W., Xiao, J., Gorski, J.N., Metzger, J.M., Lin, L.S., Thompson, C.M., Li, X., Juhl, K.,
Shang, J., Howard, A.D., Zhang, B.B., Thornberry, N.A., Reitman, M.L. and Zhou, Y.* Bombesin receptor subtype-3
(BRS-3) regulates glucose-dependent insulin secretion in mouse and human islets. For submission to: Diabetes 2010
13. Zhu Y, Olson SH, Graham D, Patel G, Hermanowski-Vosatka A, Mundt S, Shah K, Springer M,
Thieringer R, Wright S, Xiao J, Zokian H, Dragovic J, Balkovec JM. Phenylcyclobutyl triazoles as selective inhibitors
of 11beta-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett. 2008 Jun1; 18(11):3412-6.
14. Zhu Y, Olson SH, Hermanowski-Vosatka A, Mundt S, Shah K, Springer M, Thieringer R, Wright S, Xiao J, Zokian H,
Balkovec JM. 4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Bioorg Med Chem Lett. 2008 Jun 1; 18(11):3405-11
15. Aster SD, Graham DW, Kharbanda D, Patel G, Ponpipom M, Santorelli GM, Szymonifka MJ, Mundt SS, Shah K,
Springer MS, Thieringer R, Hermanowski-Vosatka A, Wright SD, Xiao J, Zokian H, Balkovec JM. Bis-aryl triazoles as
selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2008 May 1; 18 (9):2799-
804.
16. Luo, M.J., Luo, Q., Kawka, D.W., Wu, K.K., Lu, M., Wu, T., Shah, K., Ding, G.J., Koprak, S.L., Xiao, J., Legrand, C.B.,
Malkowitz, L., Dogariu, A.C., Cui, Y., Maletic, M.M., Waddell, S.T., Balkovec, J.M., Daugherty, B.L., Mudgett, J.S.,
Demartino, J.A., Detmers, P.A., Wright, S.D., Springer, M.S., Hermanowski-Vosatka, A., Koo, G.C., Cheng, K., Singer,
I.I. and Thieringer, R. 11 beta- HSD1 inhibition suppresses vascular and systemic inflammation in ApoE-/- mice.
For submission to: The Journal of Experimental Medicine,
17. Hermanowski-Vosatka A1, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger
JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer
MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R. 11beta-HSD1 inhibition
ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005 Aug 15; 202
(4):517-27.
18. Koo, G.C., K. Shah, G.J.F.Ding, J. Xiao, R.Wnek, G.Doherty, X-C. Tong, R.B. Pepinsky, K.-C. Lin, W.K.Hagmann, D.
Kawka and I.I.Singer. “A small molecule VLA4 antagonist can inhibit ovalbumin induced lung inflammation.” Am
J.Resp. Crit. Care Med. 2003 167: 1400-1409. (Micrograph used for journal cover)
19. Jinlan Zhou, Yongkang Tang, Jianming Shun, Ziqing Li, Jianying Xiao, Haiping Xiang. “Clinical Analysis of Delta
Hepatitis in 30 Patients.” The Journal of Applied Internal Medicine. (1992) 12(8): 422-423.
Abstracts
4

5. 1. Liang, L., A. Mirza, C. Gill, S.H. Lee, J. Liu, P. Mann, H. Wang, A.S. Misura, R. Huryk, A.M. Galgoci, J. Xiao, J.D.
Polishook, M. Powles, C. Tan, T. Roemer and A. Flattery. 2016. Murine Lung Infection Model Demonstrates Reduced
In Vivo Resistance Emergence to Wall Teichoic Acid Inhibitors Compared to Observed in Vitro Resistance. Abstracts
of ASM Microbe 2016 (16-20Jun2016, Boston, MA) Abstract Saturday-413.
2. Liu, J., Guiadeen, D., Krikorian, A.D., Miller, D.J., Yang, G.X., Jian, T., Blevis-bal, R., Wu, Z., Yu, Y., Sperbeck, D.M.,
Cernak, T.A., Dykstra, K.D., He, S., Lai, Z., Hong, Q., Yang, D.X., Wolff, M.S., Sonatore, L.M., Murphy, B.A., Xiao, J.,
Gorski, J.N., Pinto, S., Nargund, R.P., Shen, D., Balkovec, J.M. and Devita, R.J. Discovery of 2-
biarylbenzimidazoles as novel DGAT1 inhibitors. For presentation at: National Medicinal Chemistry 33rd Symposium,
Tucson, Arizona, 05/20/2012 - 05/23/2012.
3. Lin, h.v., chen, d., Shen, z., Zhu, l., ouyang, x., Yongs, a., Kan, y., Levorse, j.m., Kowalik jr., e.j., Szeto, d.m., Yao, x.,
xiao, j., Chen, s., Liu, j., Garcia-calvo, m., Shin, m.k. and Pinto, s. Meal-dependent regulation of gut hormones and
glucose metabolism by diacylglycerol acyltransferase-1 genetic loss-of-function and pharmacological inhibition. For
presentation at: Keystone Symposia: Genetic and Molecular Basis of Obesity and Body Weight Regulation Conference,
Santa Fe, New Mexico, 01/29/2012 - 02/03/2012.
4. Berejnaia, O., Polishook, J.D., Forrest, G., Roddy, T.P., Xiao, J., Shen, Z., Szeto, D.M., Pinto, S., Gorski, J.N. and
Hajdu, R. Development and validation of a semi-automated platform for plasma and serum clinical chemistry
measurements using microliter sample volumes. For presentation at: Society for Laboratory Automation and Screening
1st Annual Conference, San Diego, California, 02/04/2012 - 02/08/2012
5. Pinto, S., Balkovec, J.M., Carballo-Jane, E., Chen, S., Chen, D., Devita, R.J., Forrest, G., Gold, S.J., Guan, X., Gorski,
J.N., Hubert, J.A., Leavitt, P.S., Metzger, J.M., Misura, A.S., Nawrocki, A.R., Shen, Z., Szeto, D.M., Xiao, J., Marsh, D.J.
and Yoshimoto, R. Pharmacological inhibition of diacylglycerol acyltransferase 1 leads to weight loss and prolongation
of GLP-1 release. For presentation at: Keystone Symposia: Type 2 Diabetes, Insulin Resistance and Metabolic
Dysfunction and Obesity Joint Meeting, Keystone, Colorado, 01/12/2011 - 01/17/2011.
6. Yoshimoto, R., Pinto, S.*, Balkovec, J.M., Carballo-Jane, E., Chen, D., Devita, R.J., Forrest, G., Gold, S.J., Gorski, J.N.,
Hubert, J.A., Leavitt, P.S., Metzger, J.M., Misura, A.S., Nawrocki, A.R., Shen, Z., Szeto, D.M., Xiao, J., Marsh, D.J. and
Chen, S. Pharmacological inhibition of diacylglycerol acyltransferase 1 leads to weight loss and prolongation of GLP-1
release. For presentation at: Keystone Symposia: Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction and
Obesity Joint Meeting, Keystone, Colorado, 01/12/2011 - 01/17/2011
7. Zhou, Y., Feng, Y., Li, J., Xiao, J., Gorski, J.N., Metzger, J.M., Guan, X., Lin, L.S., Howard, A.D., Thornberry, N.A.,
Reitman, M.L. and Zhang, B.B. Bombesin receptor subtype-3 (BRS-3) regulates glucose-dependent insulin secretion
and glucose homeostasis. For presentation at: Keystone Symposia: Islet Biology, Whistler, Canada, 04/12/2010 -
04/17/2010.
8. Zhou, y., Feng, y., Xiao, j., Gorski, j.n., Metzger, j.m., Guan, x., lin, l.s., Howard, a.d., Thornberry, n.a., Zhang, b.b. and
Reitman, m.l. Expression of bombesin receptor subtype-3 (BRS-3) in islets from different species and its role in the
regulation of insulin secretion and glucose homeostasis. For presentation at: American Diabetes Association 70th
Annual Scientific Sessions, Orlando, Florida, 06/25/2010 - 06/29/2010.
9. Yang, X., Peterson, L.B., Thieringer, R., Deignan, J., Stepaniants, S.B., Wang, S., Wang, X., Wang, I., Beaulaurier, J.,
Nickle, D., Rosa, R.A., Cumiskey, A.M., Legrand, C.B., Luo, M.J., Luo, Q., Shah, K., Xiao, J., Schadt, E.E., Lusis, A.J.
and Lum, P.Y. Identification of causal genes for atherosclerosis in a segregating mouse population and validation via
single-gene knockout and plaque progression mouse models. For submission to: Arteriosclerosis, Thrombosis, and
Vascular Biology 2009
10. Luo, M.J., Luo, Q., Kawka, D.W., Wu, K.K., Shah, K., Lu, M., Wu, T., Ding, G.J., Koprak, S.L., Xiao, J., Legrand, C.B.,
Malkowitz, L., Dogariu, A.C., Cui, Y., Maletic, M.M., Waddell, S.T., Balkovec, J.M., Daugherty, B.L., Mudgett, J.S.,
Demartino, J.A., Detmers, P.A., Koo, G.C., Cheng, K., Hermanowski-Vosatka, A., Wright, S.D., Springer, M.S. and
Thieringer, R. Lowering glucocorticoid tone through 11 beta-HSD1 inhibition suppresses vascular and systemic
inflammation in a mouse model of atherosclerosis. For submission to: Arteriosclerosis, Thrombosis, and Vascular
Biology 2008
11. Zhou, Y., Zhang, L.W., Shah, K., Gao, L., Malkowitz, L., Li, X., Guan, Y.F., Xiao, J. Wright, S.D., Springer, M.S.,
Daugherty, B.L.* Hepatic steatosis in transgenic mice overexpressing human 11b-hydroxysteroid dehydrogenase type-1
5

6. (11b-hsd1) in adipose tissue. For presentation at: Keystone Symposia: Metabolic Syndrome and Cardiovascular Risk
Conference, Steamboat Springs, Colorado,
3/27/07 - 4/1/07.
12. Somers, E.P., Dogariu, A.C., Shah, K., Xiao, J. and Hermanowski-Vosatka, A. 11betaHSD1 inhibition improves
adipocyte function in vivo. For presentation at: North American Association for the Study of Obesity 2006 Annual
Scientific Meeting (NAASO), Boston, Massachusetts, 10/20/2006 - 10/24/2006.
13. Jianying Xiao, Kashmira Shah, Sam Koprak, Gloria Ding, Paul Fischer, Lesley McNamara, Eric Rickes, Robert Chang,
and Gloria Koo. “Role of Natural Killer Cells in Atherosclerosis in ApoE KO Mice.” P240 7th
Annual Conference on
Arteriosclerosis, Thrombosis, and Vascular Biology Meeting Apr 27-29, 2006, Denver,
14. Olson, S.H.* , Balkovec, J.M., Gao, Y., Zhu, Y., Ding, G.J.F., Hermanowski-Vosatka, A., Koo, G.C., Koprak, S.L.,
Mundt, S.S., Shah, K., Springer, M.S., Thieringer, R., Wright, S.D., Xiao, J., Zokian, H.J. “ Benzyl Triazole Inhibitors Of
11beta-Hydroxysteroid Dehydrogenase Type 1. Pharmacological Agents For The Treatment Of Metabolic Syndrome.”
For presentation at: Gordon Research Conference On Natural Products, Tilton, New Hampshire, 7/24/05 - 7/29/05
15. Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le grand, C.B., Li, Z.,
Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N., Olson, S.H., Pikounis, V.B., Ren, N., Robertson, N., Schaeffer,
J.M., Shah, K., Springer, M.S., Strack, A.M., Strowski, M.Z., Wu, K.K., Wu, T., Xiao, J., Zhang, B.B., Wright, S.D. and
Thieringer, R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis
in mice. For presentation at: Prediabetes and Metabolic Syndrome 1st Congress, Berlin, Germany, 04/12/2005 -
04/16/2005.
16. Lin, L.S., Lanza, T., Kamenecka, T., Doherty, G., Park, Y.J., Tong, X.S., Hagmann, W.K., Mumford, R.A., Mccauley, E.,
Si, Q., Pacholok, S.G., Van riper, G., Shah, K., Koo, G., Xiao, J., Egger, L.A. and Kidambi, U. Discovery of extremely
potent VLA-4 antagonists. For presentation at: Medicinal Chemistry 28th National Symposium, San Diego, California,
06/08/2002 - 06/12/2002.
17. Hang Nguyen, Jianying Xiao and Marilyn E. Morris. “Effect of Flavonoids on MRP-mediated Transport in Panc-1
Cells.” AAPS Annual Meeting. 2000
18. Jianying Xiao, Stephen Free and Jui H Wang. "The Effects of Antisense Poly-2'-O-(2,4-Dinitrophenyl)-
Oligoribonucleotides on the Expression of Slowpoke in Drosophila" 2000
19. Jianying Xiao, Xianchun Xie and Juntao Wang. “The Effect of Shuganmei on Prevention and Treatment of
Experimental Hepatic Fibrosis.” The International Chinese Conference of Hepatic Diseases, 1994.
20. Zhonghe Ji,Xianchun Xie and Jianying Xiao. “The Study of BPS on the Immunoregulation in Mice.” The 2nd National
Conference of Chinese Immunological Society, 1993.
Patents
Pharmacodynamic Assay for Inhibition of 11β-Hydroxysteroid Dehydrogenase Activity in Animal tissues
Patent No. US2004004734
6

7. (11b-hsd1) in adipose tissue. For presentation at: Keystone Symposia: Metabolic Syndrome and Cardiovascular Risk
Conference, Steamboat Springs, Colorado,
3/27/07 - 4/1/07.
12. Somers, E.P., Dogariu, A.C., Shah, K., Xiao, J. and Hermanowski-Vosatka, A. 11betaHSD1 inhibition improves
adipocyte function in vivo. For presentation at: North American Association for the Study of Obesity 2006 Annual
Scientific Meeting (NAASO), Boston, Massachusetts, 10/20/2006 - 10/24/2006.
13. Jianying Xiao, Kashmira Shah, Sam Koprak, Gloria Ding, Paul Fischer, Lesley McNamara, Eric Rickes, Robert Chang,
and Gloria Koo. “Role of Natural Killer Cells in Atherosclerosis in ApoE KO Mice.” P240 7th
Annual Conference on
Arteriosclerosis, Thrombosis, and Vascular Biology Meeting Apr 27-29, 2006, Denver,
14. Olson, S.H.* , Balkovec, J.M., Gao, Y., Zhu, Y., Ding, G.J.F., Hermanowski-Vosatka, A., Koo, G.C., Koprak, S.L.,
Mundt, S.S., Shah, K., Springer, M.S., Thieringer, R., Wright, S.D., Xiao, J., Zokian, H.J. “ Benzyl Triazole Inhibitors Of
11beta-Hydroxysteroid Dehydrogenase Type 1. Pharmacological Agents For The Treatment Of Metabolic Syndrome.”
For presentation at: Gordon Research Conference On Natural Products, Tilton, New Hampshire, 7/24/05 - 7/29/05
15. Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le grand, C.B., Li, Z.,
Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N., Olson, S.H., Pikounis, V.B., Ren, N., Robertson, N., Schaeffer,
J.M., Shah, K., Springer, M.S., Strack, A.M., Strowski, M.Z., Wu, K.K., Wu, T., Xiao, J., Zhang, B.B., Wright, S.D. and
Thieringer, R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis
in mice. For presentation at: Prediabetes and Metabolic Syndrome 1st Congress, Berlin, Germany, 04/12/2005 -
04/16/2005.
16. Lin, L.S., Lanza, T., Kamenecka, T., Doherty, G., Park, Y.J., Tong, X.S., Hagmann, W.K., Mumford, R.A., Mccauley, E.,
Si, Q., Pacholok, S.G., Van riper, G., Shah, K., Koo, G., Xiao, J., Egger, L.A. and Kidambi, U. Discovery of extremely
potent VLA-4 antagonists. For presentation at: Medicinal Chemistry 28th National Symposium, San Diego, California,
06/08/2002 - 06/12/2002.
17. Hang Nguyen, Jianying Xiao and Marilyn E. Morris. “Effect of Flavonoids on MRP-mediated Transport in Panc-1
Cells.” AAPS Annual Meeting. 2000
18. Jianying Xiao, Stephen Free and Jui H Wang. "The Effects of Antisense Poly-2'-O-(2,4-Dinitrophenyl)-
Oligoribonucleotides on the Expression of Slowpoke in Drosophila" 2000
19. Jianying Xiao, Xianchun Xie and Juntao Wang. “The Effect of Shuganmei on Prevention and Treatment of
Experimental Hepatic Fibrosis.” The International Chinese Conference of Hepatic Diseases, 1994.
20. Zhonghe Ji,Xianchun Xie and Jianying Xiao. “The Study of BPS on the Immunoregulation in Mice.” The 2nd National
Conference of Chinese Immunological Society, 1993.
Patents
Pharmacodynamic Assay for Inhibition of 11β-Hydroxysteroid Dehydrogenase Activity in Animal tissues
Patent No. US2004004734
6